 Development of an effective, accessible vaccine is the only realistic hope for halting the human immunodeficiency virus type 1 HIV-1AIDS epidemic. Ideally, such a vaccine should induce broadly neutralizing antibodies and effective T cells at the same time. Both of these goals face substantial and very different challenges, with one major roadblock in common: the enormous HIV-1 genome plasticity, i.e. ability to change and escape immune responses. There is a need to develop vaccines which may be used both prophylactically and therapeutically to either prevent HIV-1 acquisition, control its replication without HAART andor eventually eradicated the virus from the body completely. 